TELA Stock Overview
A commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s anatomy.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
TELA Bio, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.70 |
| 52 Week High | US$10.84 |
| 52 Week Low | US$4.23 |
| Beta | 1.04 |
| 11 Month Change | -15.01% |
| 3 Month Change | -12.31% |
| 1 Year Change | -53.60% |
| 33 Year Change | -70.50% |
| 5 Year Change | n/a |
| Change since IPO | -64.79% |
Recent News & Updates
Shareholders May Be More Conservative With TELA Bio, Inc.'s (NASDAQ:TELA) CEO Compensation For Now
May 29
TELA Bio, Inc. (NASDAQ:TELA) Soars 31% But It's A Story Of Risk Vs Reward
May 23Recent updates
Shareholders May Be More Conservative With TELA Bio, Inc.'s (NASDAQ:TELA) CEO Compensation For Now
May 29TELA Bio, Inc. (NASDAQ:TELA) Soars 31% But It's A Story Of Risk Vs Reward
May 23Earnings Update: TELA Bio, Inc. (NASDAQ:TELA) Just Reported Its Annual Results And Analysts Are Updating Their Forecasts
Mar 24Many Still Looking Away From TELA Bio, Inc. (NASDAQ:TELA)
Mar 08TELA Bio (NASDAQ:TELA) Has Debt But No Earnings; Should You Worry?
Oct 07Getting In Cheap On TELA Bio, Inc. (NASDAQ:TELA) Might Be Difficult
Jul 31TELA Bio: Tailwinds In Hernia Repair Market And Promising Clinical Data To Drive Accelerating Adoption
Oct 02Tela Bio prices $32M common stock offering
Aug 16Is TELA Bio (NASDAQ:TELA) Using Debt Sensibly?
May 12TELA Bio - Follow Up With Management
Jan 14Our First Look At TELA Bio
Nov 04TELA Bio Plugging Away
Oct 25TELA Bio (TELA) Investor Presentation - Slideshow
May 26Bearish: Analysts Just Cut Their TELA Bio, Inc. (NASDAQ:TELA) Revenue and EPS estimates
Mar 30Health Check: How Prudently Does TELA Bio (NASDAQ:TELA) Use Debt?
Feb 12
TELA Bio guides Q4 and FY20 revenue below consensus
Jan 14TELA Bio EPS misses by $0.09, beats on revenue
Nov 11Shareholder Returns
| TELA | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -13.6% | -0.8% | 0.07% |
| 1Y | -53.6% | -2.7% | 20.7% |
Return vs Industry: TELA underperformed the US Medical Equipment industry which returned -2.8% over the past year.
Return vs Market: TELA underperformed the US Market which returned 20.7% over the past year.
Price Volatility
| TELA volatility | |
|---|---|
| TELA Average Weekly Movement | 8.5% |
| Medical Equipment Industry Average Movement | 8.2% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in US Market | 15.3% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: TELA's share price has been volatile over the past 3 months.
Volatility Over Time: TELA's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 227 | Antony Koblish | www.telabio.com |
TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States.
TELA Bio, Inc. Fundamentals Summary
| TELA fundamental statistics | |
|---|---|
| Market cap | US$115.88m |
| Earnings (TTM) | -US$40.30m |
| Revenue (TTM) | US$63.15m |
1.8x
P/S Ratio-2.9x
P/E RatioIs TELA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TELA income statement (TTM) | |
|---|---|
| Revenue | US$63.15m |
| Cost of Revenue | US$19.22m |
| Gross Profit | US$43.93m |
| Other Expenses | US$84.23m |
| Earnings | -US$40.30m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.63 |
| Gross Margin | 69.57% |
| Net Profit Margin | -63.82% |
| Debt/Equity Ratio | 282.7% |
How did TELA perform over the long term?
See historical performance and comparison